Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (101-110 of 178) with videos related to

Pageof 18
Sort By:
Blood Advances|August 1, 2022
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MMKatharina Kriegsmann, Calin Manta, Ricarda Schwab, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Leukemia|July 21, 2018
Spectrum and functional validation of PSMB5 mutations in multiple myelomaSantiago Barrio, Thorsten Stühmer, Matteo Da-Viá, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Pageof 18

Showing results (101-110 of 178) with videos related to

Sort By:
Pageof 18
Blood Advances|August 1, 2022
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MMKatharina Kriegsmann, Calin Manta, Ricarda Schwab, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Leukemia|July 21, 2018
Spectrum and functional validation of PSMB5 mutations in multiple myelomaSantiago Barrio, Thorsten Stühmer, Matteo Da-Viá, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Pageof 18